PeptiDream EBIT

The latest EBIT for 4587.T is $-4.8B as of June 2026. That compares with $-4.2B in the prior-year period — down 15.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside PeptiDream's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4587.T's EBIT moved from $-4.2B to $-4.8B — a 15.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PeptiDream's operating scale or balance-sheet position.

Against Healthcare companies, 4587.T currently prints $-4.8B for EBIT, while the sector average sits near $110B. That is roughly 104.5% below the sector mean. Large gaps often invite a closer look at PeptiDream's growth, margins, and balance sheet.

A EBIT figure of $-4.8B for 4587.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 4587.T's EBIT ($-4.8B), review year-over-year change from $-4.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.